Dr. Quinn is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
1441 Eastlake Ave
Nor 3440
Los Angeles, CA 90089Phone+1 323-865-3111Fax+1 323-865-0061- Is this information wrong?
Summary
- Dr. David Quinn is an oncologist in Los Angeles, CA and is affiliated with multiple hospitals in the area, including Keck Hospital of USC, USC Norris Comprehensive Cancer Center, and USC Norris Comprehensive Cancer Center. He received his medical degree from University of New South Wales Faculty of Medicine and has been in practice 30 years. He specializes in genitourinary oncology and is experienced in urologic oncology and general medical oncology.
Education & Training
- University of New South Wales Faculty of MedicineClass of 1987
Certifications & Licensure
- CA State Medical License 2004 - 2025
- American Board of Radiology Therapeutic Medical Physics
Awards, Honors, & Recognition
- Best Doctors for Cancer Best Doctors
- Top Doctors Castle Connolly
- Super Doctor SuperDoctors.com
Clinical Trials
- S0421, Docetaxel and Prednisone With or Without Atrasentan in Treating Patients With Stage IV Prostate Cancer and Bone Metastases That Did Not Respond to Previous Hormone Therapy Start of enrollment: 2006 Aug 01
- Study of Gemcitabine, Oxaliplatin, and Paclitaxel in Patients With Refractory Germ Cell Carcinoma Start of enrollment: 2004 Nov 01
- Estramustine, Docetaxel, and Carboplatin for Patients With Hormone Refractory Prostate Cancer Progressing After Mitoxantrone-Based Chemotherapy. Start of enrollment: 2001 Mar 01
- Join now to see all
Publications & Presentations
PubMed
- Three- and Seven-month Prostate-specific Antigen Levels as Prognostic Markers for Overall Survival in Metastatic Hormone-sensitive Prostate Cancer: Results from SWOG S...Mamta Parikh, Catherine Tangen, Maha H A Hussain, Shilpa Gupta, Sam Callis, Yeonjung Jo, Andrea Harzstark, Channing J Paller, Saby George, Matthew R Zibelman, Heather ...> ;European Urology Oncology. 2024 Mar 23
- Markers of bone metabolism and overall survival in men with bone-metastatic hormone sensitive prostate cancer (HSPC): A subset analysis of SWOG S1216, a phase III tria...Primo N Lara Jr, Edward Mayerson, Erik Gertz, Catherine Tangen, Amir Goldkorn, Marta van Loan, Maha Hussain, Shilpa Gupta, Jingsong Zhang, Mamta Parikh, Przemyslaw Twa...> ;Prostate Cancer and Prostatic Diseases. 2024 Feb 29
- Ibrutinib combination therapy for advanced gastrointestinal and genitourinary tumours: results from a phase 1b/2 study.Do-Youn Oh, Maria Alsina Maqueda, David I Quinn, Peter J O'Dwyer, Ian Chau, Sun Young Kim, Ignacio Duran, Daniel Castellano, Jordan Berlin, Begona Mellado, Stephen K W...> ;BMC Cancer. 2023 Nov 3
- Join now to see all
Journal Articles
- Axitinib Versus Placebo as an Adjuvant Treatment for Renal Cell Carcinoma: Results from the Phase III, Randomized ATLAS TrialV Master, D I Quinn, Annals of Oncology
- Antigen-Specific CD8 Lytic Phenotype Induced by Sipuleucel-T in Hormone-Sensitive or Castration-Resistant Prostate Cancer and Association with Overall SurvivalEric J Small, David I Quinn, Clinical Cancer Research
- pembrolizumabQuinn, new england, 2017
Press Mentions
- Ground Broken on New Medical FacilityMay 3rd, 2019
- Intermittent Androgen Deprivation Not Equivalent to Continuous Treatment for Prostate Cancer, May Compromise SurvivalApril 5th, 2013
- Prostate Cancer Study Suggests Shorter TreatmentsFebruary 12th, 2016
Professional Memberships
- Member
- Member
- Fellow
- ESMOMember
- Australasian College of PhysiciansFellow
Hospital Affiliations
- Keck Hospital of USCLos Angeles, California
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: